Minimal Residual Disease Market By Product Type (Flow Cytometry, Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others), By Technology (Hematological Malignancy and Solid Tumors), By End-user (Hospitals & Specialty Clinics, Academic & Research Institutes, Diagnostic Laboratories, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
Report Overview The Minimal Residual Disease Market size is expected to be worth around US$ 6.5 billion by 2034 from US$ 2.2 billion in 2024, growing at a CAGR of 11.4% during the fo...
